Pitcairn’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,178
| Closed | -$461K | – | 573 |
|
|
2025
Q3 | $461K | Sell |
1,178
-279
| -19% | -$117K | 0.04% | 367 |
|
|
2025
Q2 | $649K | Sell |
1,457
-328
| -18% | -$151K | 0.04% | 351 |
|
|
2025
Q1 | $865K | Sell |
1,785
-99
| -5% | -$46.1K | 0.05% | 296 |
|
|
2024
Q4 | $759K | Sell |
1,884
-210
| -10% | -$97.3K | 0.04% | 311 |
|
|
2024
Q3 | $974K | Sell |
2,094
-46
| -2% | -$22.1K | 0.06% | 280 |
|
|
2024
Q2 | $1M | Buy |
2,140
+203
| +10% | +$88.1K | 0.06% | 267 |
|
|
2024
Q1 | $810K | Buy |
1,937
+150
| +8% | +$63.4K | 0.05% | 293 |
|
|
2023
Q4 | $727K | Buy |
1,787
+126
| +8% | +$46.5K | 0.05% | 295 |
|
|
2023
Q3 | $578K | Sell |
1,661
-2,614
| -61% | -$914K | 0.05% | 316 |
|
|
2023
Q2 | $1.5M | Sell |
4,275
-38
| -0.9% | -$12.8K | 0.13% | 146 |
|
|
2023
Q1 | $1.36M | Buy |
4,313
+60
| +1% | +$18K | 0.13% | 156 |
|
|
2022
Q4 | $1.23M | Sell |
4,253
-275
| -6% | -$83.8K | 0.12% | 155 |
|
|
2022
Q3 | $1.31M | Sell |
4,528
-1,831
| -29% | -$527K | 0.14% | 138 |
|
|
2022
Q2 | $1.79M | Sell |
6,359
-149
| -2% | -$39.9K | 0.19% | 104 |
|
|
2022
Q1 | $1.7M | Buy |
6,508
+520
| +9% | +$123K | 0.15% | 131 |
|
|
2021
Q4 | $1.31M | Buy |
5,988
+4,487
| +299% | +$873K | 0.08% | 171 |
|
|
2021
Q3 | $272K | Sell |
1,501
-161
| -10% | -$31.4K | 0.02% | 530 |
|
|
2021
Q2 | $335K | Sell |
1,662
-14
| -0.8% | -$2.93K | 0.02% | 468 |
|
|
2021
Q1 | $360K | Sell |
1,676
-1,450
| -46% | -$318K | 0.03% | 436 |
|
|
2020
Q4 | $739K | Sell |
3,126
-54
| -2% | -$12.4K | 0.06% | 222 |
|
|
2020
Q3 | $865K | Sell |
3,180
-26
| -0.8% | -$7.17K | 0.07% | 171 |
|
|
2020
Q2 | $931K | Buy |
3,206
+1,580
| +97% | +$428K | 0.09% | 137 |
|
|
2020
Q1 | $387K | Sell |
1,626
-34
| -2% | -$7.8K | 0.05% | 240 |
|
|
2019
Q4 | $364K | Sell |
1,660
-44
| -3% | -$8.9K | 0.03% | 330 |
|
|
2019
Q3 | $288K | Buy |
1,704
+66
| +4% | +$11.7K | 0.03% | 400 |
|
|
2019
Q2 | $300K | Sell |
1,638
-102
| -6% | -$17.8K | 0.03% | 391 |
|
|
2019
Q1 | $320K | Sell |
1,740
-65
| -4% | -$12K | 0.03% | 332 |
|
|
2018
Q4 | $299K | Sell |
1,805
-137
| -7% | -$23.7K | 0.03% | 305 |
|
|
2018
Q3 | $374K | Sell |
1,942
-7
| -0.4% | -$1.25K | 0.04% | 331 |
|
|
2018
Q2 | $331K | Sell |
1,949
-56
| -3% | -$8.68K | 0.04% | 368 |
|
|
2018
Q1 | $327K | Sell |
2,005
-58
| -3% | -$9.47K | 0.03% | 355 |
|
|
2017
Q4 | $309K | Buy |
2,063
+69
| +3% | +$10.2K | 0.03% | 381 |
|
|
2017
Q3 | $303K | Sell |
1,994
-3
| -0.2% | -$452 | 0.03% | 354 |
|
|
2017
Q2 | $257K | Hold |
1,997
| – | – | 0.03% | 377 |
|
|
2017
Q1 | $218K | Buy |
+1,997
| New | +$176K | 0.03% | 448 |
|
|
2016
Q1 | – | Sell |
-2,044
| Closed | -$257K | – | 493 |
|
|
2015
Q4 | $257K | Buy |
2,044
+22
| +1% | +$2.66K | 0.03% | 373 |
|
|
2015
Q3 | $211K | Sell |
2,022
-183
| -8% | -$23.5K | 0.03% | 378 |
|
|
2015
Q2 | $272K | Sell |
2,205
-63
| -3% | -$7.94K | 0.03% | 381 |
|
|
2015
Q1 | $267K | Buy |
2,268
+20
| +0.9% | +$2.4K | 0.03% | 401 |
|
|
2014
Q4 | $267K | Buy |
2,248
+9
| +0.4% | +$1.01K | 0.03% | 393 |
|
|
2014
Q3 | $252K | Sell |
2,239
-11
| -0.5% | -$1.05K | 0.03% | 407 |
|
|
2014
Q2 | $213K | Buy |
+2,250
| New | +$158K | 0.02% | 434 |
|
|
2014
Q1 | – | Sell |
-2,896
| Closed | -$215K | – | 497 |
|
|
2013
Q4 | $215K | Sell |
2,896
-31
| -1% | -$2.16K | 0.02% | 448 |
|
|
2013
Q3 | $222K | Sell |
2,927
-192
| -6% | -$15.3K | 0.03% | 421 |
|
|
2013
Q2 | $249K | Buy |
+3,119
| New | +$230K | 0.03% | 382 |
|
Other funds holding VRTX
Pitcairn's VRTX Position: Q4 2025 in Review
Pitcairn sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 1,178 shares — an estimated $461K sold.
Pitcairn first reported a position in VRTX in Q2 2013 and held it in 45 quarters. The position peaked at $1.79M in Q2 2022. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.
- Pitcairn reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Pitcairn sold 1,178 Vertex Pharmaceuticals shares in Q4 2025, an estimated $461K.
- Pitcairn first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 45 quarters.
- Pitcairn's Vertex Pharmaceuticals position peaked at $1.79M in Q2 2022.
- 1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.
Based on Pitcairn's 13F filing for Q4 2025.